Irinoll

Irinoll

irinotecan

Manufacturer:

Venus Remedies

Distributor:

Cosma Medical
Concise Prescribing Info
Contents
Irinotecan HCl trihydrate
Indications/Uses
Metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU therapy.
Dosage/Direction for Use
Adult Regimen 1 125 mg/m2 by IV infusion over 90 min on days 1, 8, 15 & 22 followed by leucovorin & 5-FU. Repeat cycle course every 6 wk. Regimen 2 180 mg/m2 by IV infusion over 90 min on days 1, 15 & 29 followed by leucovorin & 5-FU on days 1, 2, 15, 16, 29 & 30. Next cycle course begins on day 43.
Contraindications
Special Precautions
Early & late forms of diarrhea. Ensure fluid & electrolyte replacement upon dehydration. Severe myelosuppression. Monitor for signs of inflammation in infusion site, WBC w/ differential Hb & platelet count before each dose. Administer antiemetic agents 30 min prior to treatment. Consider prophylactic & therapeutic administration of atropine SC. Patients who had previously received pelvic/abdominal irradiation. Hepatic dysfunction. Gilbert's syndrome. Women of child-bearing potential should avoid becoming pregnant. Pregnancy & lactation. Elderly
Adverse Reactions
Nausea, vomiting, diarrhea; neutropenia, leucopenia (including lymphocytopenia), anemia; asthenia, fever, abdominal pain; cholinergic symptoms; liver enzyme abnormalities; alopecia, rashes; dyspnea, insomnia, dizziness; vasodilation, bradycardia.
Drug Interactions
May enhance hyperglycemia w/ dexamethasone.
ATC Classification
L01CE02 - irinotecan ; Belongs to the class of Topoisomerase 1 (TOP1) inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Irinoll infusion 100 mg/5 mL
Packing/Price
1's
Form
Irinoll infusion 40 mg/2 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in